• Explore /
  • Poster
  • / Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).

Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).

Abstract Poster

Authors

Neil Iyengar

Neil M. Iyengar

Memorial Sloan-Kettering Cancer Center, New York, NY

Neil M. Iyengar , Patrick Glyn Morris , Sujata Patil , Carol Chen , Alyson Abbruzzi , Robert James Lehman , Richard Steingart , Kevin C. Oeffinger , Nancy U. Lin , Beverly Moy , Steven E. Come , Eric P. Winer , Larry Norton , Clifford Hudis , Chau T. Dang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Breast Cancer Symposium

Session Type

Poster Session

Session Title

General Poster Session B

Track

Survivorship and Health Policy,Systemic Therapy

Sub Track

HER2+

Clinical Trial Registration Number

NCT00591851 and NCT00482391

Citation

J Clin Oncol 31, 2013 (suppl 26; abstr 167)

DOI

10.1200/jco.2013.31.26_suppl.167

Abstract #

167

Poster Bd #

E4

Abstract Disclosures

Similar Posters

First Author: Patrick Glyn Morris

First Author: C. T. Dang

First Author: Rui Wang

Poster

2014 ASCO Annual Meeting

Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.

Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.

First Author: Pooja Prem Advani